GHK-Cu: delivery and skin measurements

Copper Tripeptide-1

GHK is glycine-histidine-lysine, a short amino-acid chain. GHK-Cu is its copper(II) complex, also called Copper Tripeptide-1 in cosmetics. The copper-bound and free forms appear in different experiments, so a finding about GHK needs its chemical identity carried along.

The skin-regeneration review describes a peptide with an unusually long cosmetic story. GHK was isolated from human plasma in 1973, and its sequence also occurs in collagen and in SPARC/osteonectin. That biological origin helps explain the interest. I need a therapeutic result before crediting the familiar chemistry with a benefit.

Stratum corneum

The 2025 anti-wrinkle review spends considerable effort on delivery through the stratum corneum, the skin's outer barrier. Poor penetration complicates the otherwise appealing account of stimulating repair cells. Formulation changes such as palmitoylation and microneedle pretreatment are research approaches to that obstacle; their results are specific to the tested preparation.

In the ex vivo human skin penetration experiment, copper applied as GHK-Cu passed through dermatomed skin and formed a dermal depot. The measured quantities were copper. The experiment used removed human tissue, so it provides neither a whole-body exposure study nor a human injection result.

For me, that physical barrier is more interesting than an expansive list of proposed uses. An active molecule still has to arrive at the relevant tissue in an intact and useful form. There is no validated human pharmacokinetic basis for injectable or systemic GHK-Cu in this record.

Collagen and expression signatures

The gene-expression analysis discussed in the 2018 review reports changes in approximately 31.2% of human genes at a 50%-or-greater threshold, with 59% of affected genes increased and 41% suppressed. These are database and cell-level findings involving GHK. They require validation beyond the expression signature before broad clinical conclusions follow.

I’m sceptical of a benefit score based on counting changed genes. Gene expression describes how strongly cells use genetic instructions; the consequences depend on which cells, which instructions and the setting. The widely repeated figure of about 4,000 genes is an extrapolation, while the table at that threshold reports on the order of 2,100.

The review describes collagen, dermatan sulfate, chondroitin sulfate and decorin synthesis in cultured dermal fibroblasts. Matrix-building and matrix-remodelling enzymes both feature in this cell-culture work. Chondroitin sulfate may sound especially relevant to cartilage, but the synthesis discussed here occurred in cultured dermal fibroblasts. It leaves a human joint-surface claim untested.

Human skin and hair outcomes

The review of topical clinical findings reports increased collagen production in 70% of treated women, compared with 50% for vitamin C and 40% for retinoic acid. These percentages describe the share with increased production, rather than the size of a collagen increase. The small topical literature concerns appearance and skin measurements.

The six-month hair study in 45 men with androgenetic alopecia reported hair-count increases of 52.6 and 71.5 in the active groups, compared with 9.6 for placebo. The formulation combined 5-aminolevulinic acid with glycyl-histidyl-lysine peptide. I grant that combination its observed result; attributing it wholly to pure GHK-Cu would give the copper peptide credit the experiment cannot allocate.

Neither these topical outcomes nor the gene-expression findings establishes a systemic anti-aging effect or human cartilage restoration. The recent topical review makes a more bounded place to begin than a claim about rejuvenating the whole body.

Irritation, copper and route

Skincare accounts describe firmer-feeling skin, softer lines, hydration and thicker-looking hair. Complaints include stinging, redness, dryness, breakouts and occasional darker or patchier pigment. Research-use injection accounts add local swelling or bruising. All of these are anecdotal accounts rather than clinical evidence; they cannot supply an incidence rate or establish an injectable benefit.

Copper chemistry deserves care on its own terms. The formulation review discusses instability and compatibility concerns, including strong reducing agents or low-pH conditions. The intact copper complex and a degraded preparation can behave differently. A theoretical copper-accumulation concern applies to systemic exposure, particularly with copper-handling disorders such as Wilson's disease; clinical accumulation from GHK-Cu has not been studied in those people. This concern cannot simply be transferred to ordinary topical cosmetic use.

Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK. GHK-Cu has no FDA- or EMA-approved drug indication, and injection or systemic use remains unapproved. Its absence by name from the 2024–2025 WADA lists gave no blanket clearance: S0 can cover non-approved pharmacological substances. I attach far more weight to the tested route and formulation than to the reassuring sound of the word copper.